hCD3EDG/hBCMA(BALB/c)
Nomenclature
BALB/cJSmo-Bcmatm1(hTNFRSF17)Cd3etm1(hCD3E)Cd3dtm1(hCD3D)Cd3gtm1(hCD3G)Smoc
Cat. NO.
NM-XA-250066
Strain State
Repository Live
Model Description
Validation Data
Fig.1 Detection of hBCMA expression on TACI+CD138+ cells in spleen and bone marrow of WT BALB/c mice and HO hCD3EDG/hBCMA(BALB/c) mice by FACS. Leukocytes were collected from wild-type BALB/c mice (female, 8 weeks old) and homozygous hCD3EDG/hBCMA(BALB/c) humanized mice (female, 7 weeks old), and analyzed by flow cytometry with anti-hBCMA.
Abbr. HO, homozygous; WT, wild type.
Fig 2. Frequency of leukocyte and myeloid subpopulations in the spleen by flow cytometry
Spleen was collected from WT BALB/C mice and HO/HO hCD3EDG/hBCMA(BALB/C) mice (7-week-old, n=3). Flow cytometry analysis of frequencies of (A) lymphocyte and (B) myeloid subpopulations in the spleen. Bar indicated expressed as mean ± SEM.
Abbr. HO/HO, homozygous; WT, wild type.
Fig 3. Frequency of leukocyte and myeloid subpopulations in the BM by flow cytometry
BM was collected from WT BALB/C mice and HO/HO hCD3EDG/hBCMA(BALB/C) mice (7-week-old, n=3). Flow cytometry analysis of frequencies of (A) lymphocyte and (B) myeloid subpopulations in the BM. Bar indicated expressed as mean ± SEM.
Abbr. HO/HO, homozygous; WT, wild type.
Fig 4. Frequency of leukocyte and myeloid subpopulations in the blood by flow cytometry
Blood was collected from WT BALB/C mice and HO/HO hCD3EDG/hBCMA(BALB/C) mice (7-week-old, n=3). Flow cytometry analysis of frequencies of (A) lymphocyte and (B) myeloid subpopulations in the blood. Bar indicated expressed as mean ± SEM.
Abbr. HO/HO, homozygous; WT, wild type.
Table 1. Blood routine examination of hCD3EDG/ hBCMA(BALB/c) knockin mice. Values are expressed as mean±SEM.
Abbr. HO, homozygous; WT, wild type.
Fig 5. In vivo efficacy study of teclistamab in HO hCD3EDG/hBCMA(BALB/c) mice.
Teclistamab were injected at day 0, 3, 5, and immune cells in the spleen and bone marrow of mice after therapy were measured by flow cytometry (n=4). Values are shown as mean ± SEM.
You may also like
Workshop：Progress and Advances in Preclinical immuno-Oncology Research
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Learn moreShanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreCustomizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more
